1. Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction
- Author
-
Marta Noris Mora, Pere Pericas, Vicente Peral Disdier, Xavier Rossello, Caterina Mas-Lladó, Rosa González Colino, José Francisco Forteza Albertí, Maria F Ramis-Barceló, Isabel Valadrón, and Lucía Pasamar Márquez
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,Time Factors ,Diastole ,Tetrazoles ,Sacubitril ,Ventricular Function, Left ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Internal Medicine ,medicine ,Humans ,Protease Inhibitors ,Longitudinal Studies ,Prospective Studies ,Aged ,Heart Failure ,Ejection fraction ,business.industry ,Aminobutyrates ,Biphenyl Compounds ,Stroke Volume ,Recovery of Function ,Middle Aged ,medicine.disease ,Drug Combinations ,030104 developmental biology ,medicine.anatomical_structure ,Treatment Outcome ,Valsartan ,Ventricle ,Echocardiography ,Heart failure ,Cohort ,Cardiology ,Female ,Neprilysin ,Cardiology and Cardiovascular Medicine ,business ,Angiotensin II Type 1 Receptor Blockers ,030217 neurology & neurosurgery ,Sacubitril, Valsartan ,medicine.drug - Abstract
Sacubitril/valsartan (S–V) has been shown to reduce clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF). This benefit has been mostly attributed to an improvement in systolic function. This study aimed to evaluate longitudinal changes in several echocardiographic parameters of diastolic function in a cohort of patients with HFrEF receiving S–V. Echocardiographic parameters of consecutive patients receiving S–V, such as diastolic dysfunction (DD) grade and other individual diastolic and systolic function parameters, were prospectively collected at baseline and at 6-month follow-up. New York Heart Association (NYHA) functional class was also recorded. 65 patients (73.9% males; 61.5 ± 13 years) with HFrEF in NYHA class II–IV were evaluated. There was a significant reduction in DD grade after treatment with maximal tolerated doses (p
- Published
- 2020